Reverse split has zero to do with the company being legit or not. Plenty of legit companies have done RS in the past. If the company sucks, it sucks. RS may crater HTBX's stock price even further, but if they have something that's worthwhile (and some management that isn't totally inept), RS won't matter. As an investor, I'd be more interested in their products/IP and their management. RS at a biotech company at this stage is just noise.
I have a miniscule position in HTBX and I'm more concerned about management and IP than I am about my small position becoming smaller. I can tell you that there was nothing about them that impressed me enough to take a large position. I think their zika vaccine was a red herring which makes me skeptical of the rest of their "pipeline". Hopefully BP sees potential.
News 
Market Data 
Discover 
